

—Maria de Fatima Maroja, M.D.

*Instituto de Dermatologia e
Venereologia Alfredo da Matta
Manaus, Amazonia, Brazil*

—Philippe Cruaud, M.Sc. (Pharm.)

*Unité de la Tuberculose
et des Mycobactéries
Institut Pasteur
25 Rue du Dr. Roux
Paris, France*

Acknowledgment. We thank Dr. F. Papa (Unité de la Tuberculose et des Mycobactéries, Institut Pasteur) for supplying the PGL-I antigen; to Dr. A. T. Orsi-Souza (Instituto de Dermatologia e Venereologia Alfredo de Matta) for supplying lepromin-H; and the colleagues and nurses of the Instituto de Dermatologia e Venereologia Alfredo da Matta for their invaluable help in the classification and monitoring of the patients.

REFERENCES

1. CRUAUD, P., YAMASHITA, J. T., MARTIN-CASBONA, N., PAPA, F. and DAVID, H. L. Evaluation of a novel 2, 3-diacyl-trehalose-2' sulfate for case finding and diagnosis of leprosy and tuberculosis. *Res. Microbiol.* **141** (1990) 679–694.
2. DAVID, H. L. The spectrum of tuberculosis and leprosy; what can be the significance of specific humoral responses? *Res. Microbiol.* **141** (1990) 197–206, 263–265.
3. HUNTER, S. W. and BRENNAN, P. J. A novel phenolic glycolipid from *Mycobacterium leprae* possibly involved in immunogenicity and pathogenicity. *J. Bacteriol.* **147** (1981) 728–735.
4. HUNTER, S. W., FUJIWARE, T. and BRENNAN, P. Structure and antigenicity of the major specific glycolipid antigen of *Mycobacterium leprae*. *J. Biol. Chem.* **257** (1982) 15072–15078.
5. PAPA, F., CRUAUD, P. and DAVID, H. L. Antigenicity and specificity of selected glycolipid fractions from *Mycobacterium tuberculosis*. *Res. Microbiol.* **140** (1989) 569–578.
6. RIDLEY, D. S. and JOPING, W. H. Classification of leprosy according to immunity; a five-group system. *Int. J. Lepr.* **34** (1966) 255–273.
7. SCHWERER, B., MEEKER, H. C., SERSEN, G. and LEVVIS, W. R. IgM antibodies against phenolic glycolipid-I from *Mycobacterium leprae* in leprosy; relationship to bacterial index and erythema nodosum leprosum. *Acta Leprol. (Genève)* **95** (1984) 395–402.
8. SHEPARD, C. C. Immunity to leprosy and the Mitsuda reaction. *Int. J. Lepr.* **52** (1984) 74–77.
9. YOUNG, D. B. and BUCHANAN, T. M. A serological test for leprosy with a glycolipid specific for *Mycobacterium leprae*. *Science* **221** (1983) 1057–1059

Circulating Antispermatozoal Antibodies in Leprosy

TO THE EDITOR:

The presence of autoantibodies in leprosy, especially in lepromatous leprosy, has been widely investigated. Autoantibodies have been found against almost all body tissues, cellular and nuclear material, and immunoglobulins (8).

Autoantibodies reacting with testicular germinal cells and spermatozoa have been reported in both tuberculoid and lepromatous patients (7,9). Antibodies may be formed because of antigenic similarity between *Mycobacterium leprae* and testicular tissue or due to an adjuvant-like action of *M. leprae*. Various studies have given widely varying figures, probably because of the various techniques employed to check the presence of antispermatozoal antibodies (ASA).

The present study was undertaken keeping in mind the widely variable results and

tests employed not permitting a scientific comparison.

Subjects and serum samples. Sera from 30 healthy men of proven fertility and 68 male leprosy (bacillary-positive BL, LL) patients were obtained. The duration of disease varied from 1 to 14 years. None of the patients had or gave a history of erythema nodosum leprosum in the recent past, reasonably confirmed by taking a relevant history and asking leading questions.

Blood samples were collected in vacuum tubes, centrifuged at 1500 × g and the sera were separated and frozen at –70°C within 3 hr of collection. Decomplementation of the sera was done before performing the sperm agglutination test (SAT⁴) and the sperm immobilization test (SIT³). A titer of ≥ 1:8 was considered positive for the SAT. A sperm immobilization value of > 2.0 constituted a positive SIT result.

TABLE 1. Detection of antisperm antibodies in the sera of patients and controls by three different tests.

	No. tested	SAT ^a		SIT ^b		ELISA	
		No. positive	%	No. positive	%	No. positive	%
Controls	30	2	6.6%	0	0%	2	6.6%
Leprosy patients	68	9	13.6%	5	7.35%	16	23.5%

^a Sperm agglutination test.

^b Sperm immobilization test.

Sperm preparation. A pool of normal spermatozoa obtained from a group of healthy fertile men served as antigen. The pooled specimen was diluted 1:10 with PBS-EGTA. The suspension was centrifuged at $500 \times g$ for 25 min for sedimentation of the sperm. The sediment was resuspended in PBS-EGTA and was warmed to 37°C. The washing procedure was repeated three times and finally resuspended to a final concentration of 6×10^6 sperm/ml.

ELISA. The ASAs were assessed by the method of Witkin (¹⁰) using an enzyme-linked immunosorbent assay (ELISA). The class of antibody bound to spermatozoa was determined by the use of 0.2 ml of heavy-chain specific, alkaline-phosphatase conjugated, goat anti-human IgG, IgA, or IgM (Sigma Chemical Co., St. Louis, Missouri, U.S.A.) diluted 1:1000 in the Tween wash.

Results. The percentage positivity ASAs detected in leprosy sera was highest with the ELISA (23.5%) compared to the SAT and SIT methods. The figures obtained from controls were 6.6% by the same method (Table 1).

Table 2 summarizes the distribution of IgG, IgA, and IgM antibodies in serum. Evidently the IgA and IgM classes of antibodies reacted more often with the sperm antigen as compared to IgG immunoglobulins.

Discussion. In leprosy both the spermatogenic and androgenic function of the

testes are affected, although the former usually precedes the later (¹). The concept of immunofertility has been widely accepted since the antigenicity of spermatozoa was first demonstrated by Landsteiner (⁵). Disruption of the blood testes barrier is probably a requisite for antisperm antibody formation. In leprosy patients they may either be produced as a result of a generalized autoimmune mechanism, more so in lepromatous disease, or due to direct damage to testicular tissue in general or germinal epithelium by leprosy bacilli due to blockage of efferent ducts. Immunological injury may thus play a significant role in the pathogenesis of testicular involvement. Testicular biopsies, even in tuberculoid patients with positive antisperm antibodies, showed changes suggestive of immune damage (²).

Antispermatozoal antibodies may affect reproduction by mechanisms such as agglutination or immobilization of spermatozoa, serum cytotoxicity, impairment of sperm penetration of ova membranes, and enhanced phagocytosis of sperm in the genital tract by macrophages (⁶).

The different antigenic determinants on human spermatozoa might produce different types of antibodies which could be detected by sperm agglutination, sperm immobilization, sperm hemagglutination, or ELISA. False-positive or -negative results by the ELISA are extremely rare. A proper correlation of the various figures in different

TABLE 2. Distribution of antisperm antibodies of IgG, IgA, and IgM types in sera in controls and leprosy patients.

	Total no.	IgG		IgA		IgM	
		No. positive	%	No. positive	%	No. positive	%
Controls	30	0	0%	2	6.7%	1	3.3%
Leprosy patients	68	5	7.5%	12	18.0%	15	22.5%

studies is possible only if a uniform standard method is employed for the detection of ASA, otherwise all comparison would be unfair and unrewarding. Although all three classes of antibodies were elevated in multibacillary patients, IgM showed greater elevation which may be due to the unmasking of specific antigenic determinants by the disease process.

Wall and Wright⁽⁹⁾ found antispermatozoal antibodies in 44 out of 50 patients (74.6%) with lepromatous disease and in 4 out of 10 patients (40%) with tuberculoid disease. Gupta, *et al.*⁽²⁾ reported incidences of 39.4% and 33.3% in lepromatous and tuberculoid patients, respectively, by SIT which they thought was the best test compared to SAT and the sperm hemagglutination test.

In the present study, the low degree of positivity (23.3%) in lepromatous patients obtained by a sensitive ELISA does not correspond with the high percentage positivity obtained by Wall and Wright and Gupta, *et al.* So, in addition to the prolonged disease, there must be other unidentified causes responsible for the reported testicular dysfunction and histopathological abnormalities.

—Bhushan Kumar, M.D., M.N.A.M.S.

Additional Professor
Department of Dermatology

—S. Majumdar, M.D., Ph.D.

Additional Professor
Department of Experimental Medicine
Postgraduate Institute of Medical
Education and Research
Chandigarh 160012, India

REFERENCES

1. EL-SHIEMY, S., EL-HEFNAWI, H., ABDEL-FATTAH, A., EL-OKBI, M. and FARID, A. Testicular and epididymal involvement in leprosy patients, with special reference to gynecomastia. *Int. J. Dermatol.* **15** (1976) 52–28.
2. GUPTA, S. C., BAJAJ, A. K. and SINGH, P. A. Testicular biopsy in antispermatozoal antibody positive tuberculoid leprosy patients. (Letter) *Int. J. Lepr.* **52** (1984) 255.
3. ISOJIMA, S. and TSUZUKU, O. Problem of ABO blood group incompatibility and sterility: the effect of blood group antibody on spermatozoa. *Am. J. Obstet. Gynecol.* **102** (1968) 304–306.
4. KIBRICK, S., BELDING, D. L. and MERRILL, B. Methods for the detection of antibodies against mammalian spermatozoa. II. A gelatin agglutination test. *Fertil. Steril.* **3** (1952) 430–438.
5. LANDSTEINER, K. Sur Kenntnis der spezifisch auf blutkörperchen wirkenden sera. *Centralbl. Bakteriolog. Parasitol. Infekt.* **25** (1899) 546–549.
6. McSHANE, P. M. Immunologic aspects of male infertility. *Semin. Urol.* **2** (1984) 107–114.
7. SAHA, K. and GUPTA, I. Immunologic aspects of leprosy with special reference to the circulating antispermatozoal antibodies. *Int. J. Lepr.* **45** (1975) 28–37.
8. SEHGAL, S. and KUMAR, B. Circulating and tissue immune complexes in leprosy. *Int. J. Lepr.* **49** (1981) 294–391.
9. WALL, J. R. and WRIGHT, D. J. M. Antibodies against testicular germinal cells in lepromatous leprosy. *Clin. Exp. Immunol.* **17** (1974) 51–59.
10. WITKIN, S. S. Enzyme linked immunosorbent assay (ELISA) for detection of antibodies to spermatozoa. *Res. Reprod.* **15** (1983) 1–4.